Semaglutide added about 100 days of life to old mice and kept their strength and memory

Female mice that began taking semaglutide at 20 months of age lived about 100 days longer than untreated mice, according to a study from the University of California, Berkeley published in Nature in September 2026. The treated animals also held on to physical and mental abilities that normally fade in old age, including strength, balance and memory, which is what makes the finding more than a longevity curiosity. Extending life in a lab animal is common enough; keeping the animal capable and sharp through those added weeks is harder to achieve and closer to what people mean when they talk about healthy aging.

The drug is the same compound sold for diabetes and weight loss, and the result has fueled speculation about whether it might slow aging itself. The work was done entirely in mice, and the scientists involved are careful about how far it can be stretched. What follows sets out what the mice were given, how the drug fared against a calorie-restricted diet, and what the National Institute on Aging’s own senior investigator says the result does and does not show.

What the mice received and what they kept

The study, titled “Late-life semaglutide treatment slows ageing and extends lifespan in female mice”, was led by Dr. Danica Chen at Berkeley and funded in part by the National Institute on Aging. Mice started daily semaglutide at 20 months, an age that corresponds roughly to the later years of a mouse’s life, and NIH’s summary of the work reports that those treated until death lived about 100 days longer than untreated animals.

Lifespan was only part of the picture. After three months of daily dosing, treated mice outperformed controls on measures that typically decline with age, including muscle function, cognitive function, coordination, balance and endurance. Because the treatment started late, at 20 months and not in youth or middle age, the benefits cannot be explained as the product of a lifetime of lower body weight or early metabolic protection. Semaglutide also reversed age-related shifts in the activity of a range of genes, which hints that the drug was acting on the biology of aging and not only on the symptoms.

The choice of female mice matters for reading the result, because lifespan studies in animals often produce different answers by sex and a single-sex finding is a narrower claim than a general one. The paper’s own title restricts its claim to females, and the NIH account does not describe a comparable male group, so the finding should not be assumed to apply to both sexes. Readers weighing that figure should also keep in mind that the roughly 100-day gain is an average across treated animals compared with untreated ones, not a guarantee for any individual mouse.

Semaglutide against calorie restriction

Calorie restriction is the best-established intervention for extending lifespan in laboratory animals, so the researchers ran a second experiment to see how semaglutide compared. One group of old mice received semaglutide for five months, while another ate a diet with 24 percent fewer calories for the same period. Both approaches prevented declines in physiological functions linked to aging, which means the drug matched the diet on the basics.

Where they diverged is the notable part. Only semaglutide improved exploratory behavior, spatial memory and glucose tolerance, according to the PubMed record of the Nature paper and the NIH write-up built on it. Memory, in other words, was something the drug protected and the diet did not, at least in the tests used.

The energy data point to different mechanisms. Calories eaten were comparable between the two groups, yet the calorie-restricted mice slowed their daytime energy use, while the semaglutide mice did not change theirs. A drug that delivers some of the benefits of eating less without forcing the body into an energy-saving state is an appealing idea, though the experiment does not explain why the effects differ. The finding does suggest that the benefits of GLP-1 drugs in aging animals are not simply a stand-in for eating less, and that different interventions may reach different parts of the aging process, a point that will shape how future studies are designed and compared.

How far a mouse result travels

Dr. Rafael de Cabo, a senior investigator at the National Institute on Aging, put the significance in terms of disease. “Most chronic diseases are deeply rooted in the aging process,” he said, adding that if GLP-1 agonists do slow it down, a wide range of clinical benefits is exactly what would be expected. His point is that a drug acting on aging should show up across many conditions at once, which is consistent with the broad improvements the mice displayed across muscle, balance, endurance and cognition.

He also supplied the caution. Mice carry the same GLP-1 receptor that semaglutide targets, which makes them a reasonable test case, but de Cabo noted that mouse results do not always translate directly to people, and NIH’s write-up states that more research is needed to confirm the findings before firm conclusions are drawn. No human trial of semaglutide as an anti-aging treatment is part of this work, and nothing in it supports taking the drug for that purpose.

The broader scientific question of whether aging can be slowed at all is covered in an NIH explainer on slowing aging, which sits alongside this study in the agency’s research highlights. For people looking for steps with a human evidence base today, the National Institute on Aging maintains guidance on healthy eating, nutrition and diet.

The next steps are the ones the Berkeley result leaves open: whether the benefit appears in male mice, whether it holds in other species, and whether any of it carries over to human aging. Until those answers arrive, the study stands as a carefully documented signal in mice, and a reason for researchers to look harder at what GLP-1 drugs do beyond blood sugar and body weight.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview